Imeglimin - Poxel

Drug Profile

Imeglimin - Poxel

Alternative Names: EMD-387008; PXL 008; RVT-1501

Latest Information Update: 12 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Poxel
  • Class Amines; Antihyperglycaemics; Small molecules; Triazines
  • Mechanism of Action AMP activated protein kinase stimulants; Glucose modulators; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 08 Oct 2018 Poxel completes enrolment in the TIMES 2 phase III trial for Type-2 diabetes mellitus in Japan
  • 26 Sep 2018 Poxel prematurely terminated a phase IIa trial in Type-2 diabetes mellitus (In volunteers) in Germany (EudraCT2016-003215-35)
  • 30 Aug 2018 Imeglimin - Poxel is available for licensing as of 30 Aug 2018. www.poxelpharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top